PALO ALTO, Calif., Jan. 16, 2024 /PRNewswire/ -- Evommune, Inc., a clinical stage biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases, today announced the initiation of its Phase 1 first-in-human study, evaluating EVO756 in heathy adults and adults with chronic spontaneous urticaria (CSU).

加利福尼亚州帕洛阿尔托，2024年1月16日/PRNewswire/--Evommune，Inc.，一家临床阶段生物技术公司，发现并开发治疗免疫介导的炎症性疾病的新方法，今天宣布启动其第一阶段人体研究，评估健康成年人和慢性自发性荨麻疹（CSU）成年人的EVO756。

By blocking MRGPRX2 activation and degranulation of mast cells, EVO756 has the potential to be a first-in-class oral treatment for a variety of mast cell-mediated diseases, including chronic spontaneous urticaria and inflammatory itch..

通过阻断肥大细胞的MRGPRX2活化和脱粒，EVO756有可能成为多种肥大细胞介导的疾病（包括慢性自发性荨麻疹和炎性瘙痒）的一流口服治疗药物。。

'As a company committed to developing a pipeline of therapeutics to halt the progression of chronic inflammatory diseases, we are excited to dose the first volunteer in our Phase 1 trial of EVO756,' said Eugene Bauer, M.D., Chief Medical Officer at Evommune. 'By targeting mast cells via the selective modulation of MRGPRX2, we aim to deliver a novel therapeutic with the efficacy of a biologic and the potential for once-daily oral administration, without the safety challenges of alternative mast cell depleting options.

Evommune首席医疗官医学博士尤金·鲍尔（EugeneBauer）说：“作为一家致力于开发阻止慢性炎症性疾病进展的治疗药物的公司，我们很高兴为EVO756第一阶段试验的第一名志愿者服用药物。”通过选择性调节MRGPRX2靶向肥大细胞，我们的目标是提供一种具有生物学功效和每日一次口服给药潜力的新型治疗剂，而无需替代肥大细胞消耗选择的安全性挑战。

In CSU patients, blockade of the MRGPRX2 receptor and its subsequent downstream effect has the potential to treat the root cause of inflammation, offering greater relief than currently available treatments.'.

在CSU患者中，阻断MRGPRX2受体及其随后的下游效应有可能治疗炎症的根本原因，比目前可用的治疗方法提供更大的缓解。

The Phase 1 study is a randomized, double-blind, placebo-controlled single and multiple ascending dose (SAD and MAD) study in normal healthy adults and an open label study in adults with CSU. The study is designed to assess the safety, tolerability, and pharmacokinetics, of orally administered EVO756.

第一阶段研究是一项针对正常健康成年人的随机，双盲，安慰剂对照单次和多次递增剂量（SAD和MAD）研究，以及针对CSU成年人的开放标签研究。该研究旨在评估口服EVO756的安全性，耐受性和药代动力学。

The pharmacodynamic potential of EVO756 on mast cell degranulation will be assessed in a skin challenge test, in which a known ligand of the X2 receptor is administered intradermally, resulting in measurable skin responses in healthy adults and adults with CSU. This portion of the study will be done in collaboration with Sarbjit Saini, M.D., Johns Hopkins University, and allows for an evaluation of patients in a highly controlled setting, and also has the benefit of mimicking the impact of EVO756 versus a control against inducible urticarias in the healthy adult cohort..

EVO756对肥大细胞脱颗粒的药效学潜力将在皮肤激发试验中进行评估，其中皮内施用已知的X2受体配体，从而在健康成年人和CSU成年人中产生可测量的皮肤反应。这部分研究将与约翰·霍普金斯大学医学博士Sarbjit Saini合作完成，可以在高度受控的环境中对患者进行评估，还可以模拟EVO756的影响，而不是在健康成人队列中控制诱导性荨麻疹。。

About EVO756

关于EVO756

EVO756 is a potent, highly selective small molecule antagonist of mas-related G-protein coupled receptor X2 (MRGPRX2). MRGPRX2 is most abundantly found on mast cells and peripheral sensory neurons. MRGPRX2 can trigger IgE-independent activation (degranulation) via multiple ligands, which can lead to a variety of symptoms depending on the tissue that is affected.

EVO756是mas相关G蛋白偶联受体X2（MRGPRX2）的有效，高选择性小分子拮抗剂。MRGPRX2在肥大细胞和外周感觉神经元上最为丰富。MRGPRX2可以通过多种配体触发IgE非依赖性激活（脱粒），这可能导致多种症状，具体取决于受影响的组织。

Evommune's pre-clinical data demonstrates that by blocking activation of MRGPRX2 and degranulation of mast cells, EVO756 has the potential to be a first-in-class oral treatment for a variety of mast cell mediated diseases. In addition, due to its unique function on peripheral sensory neurons, EVO756 could provide fast relief of itch associated with inflammatory diseases, such as atopic dermatitis.

Evommune的临床前数据表明，通过阻断MRGPRX2的激活和肥大细胞的脱粒，EVO756有可能成为各种肥大细胞介导疾病的一流口服治疗药物。此外，由于其对外周感觉神经元的独特功能，EVO756可以快速缓解与炎症性疾病（如特应性皮炎）相关的瘙痒。

EVO756 represents a new, targeted approach to the treatment of these disorders with the potential for once-daily oral administration without the serious side effects observed with other approaches..

EVO756代表了一种新的，有针对性的治疗这些疾病的方法，有可能每天口服一次，而没有其他方法观察到的严重副作用。。

About Evommune, Inc.

关于Evommune，Inc。

Evommune, Inc., a Palo Alto based biotech company, is creating game-changing science to treat immune-mediated inflammatory diseases by discovering, developing, and delivering therapies that address symptoms and halt progressive disease. For more information, please visit Evommune.com.

Evommune，Inc.，一家总部位于帕洛阿尔托的生物技术公司，正在创造改变游戏规则的科学，通过发现、开发和提供治疗症状和阻止进行性疾病的疗法来治疗免疫介导的炎症性疾病。有关更多信息，请访问Evommune.com。

Contact:Paul Laland415.519.6610[email protected]

联系人：Paul Laland415.519.6610[受电子邮件保护]

SOURCE Evommune, Inc.

SOURCE Evommune公司。